CXCR4 Antibody MAB172-100 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemCXCR4 Antibody
CompanyR&D Systems, a Bio-Techne Brand
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberMAB172-100
Quantity100 ug (also 25 ug)
ApplicationsFlow Cytometry, Immunohistochemistry, Neutralization, CyTOF-ready
Conjugate/TagUnconjugated
ReactivityHuman
TargetCXCR4
IsotypeIgG2b
Clone44716
HostMouse
NCBI Full Gene NameC-X-C motif chemokine receptor 4
NCBI Gene AliasesCD184, D2S201E, FB22, HM89, HSY3RR, LAP-3, LAP3, LCR1, LESTR, NPY3R, NPYR, NPYRL, NPYY3R, WHIM, WHIMS, WHIMS1
ClonalityMonoclonal
FormatLyophilized from a 0.2 µm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS
Immunogen3T3 cells transfected with human CXCR4
ConcentrationLYOPH
Brand/TrademarkR&D Systems, a Bio-Techne Brand
PurityProtein A or G purified from hybridoma culture supernatant
Antibody TypePrimary Antibodies
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution

Available conjugates: Unconjugated

Specificity: Detects human CXCR4. It will also react with cells expressing feline CXCR4 but not rat CXCR4

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

(1) Analysis of the chemotactic factors for tumor-infiltrating fibrocytes and their prognostic significances in lung cancerOncology lettersNovember 1, 2022Tobiume M, Mitsuhashi A, Saijo A, Ogino H, Afroj T, Ogawa H, Goto H, Sato S, Abe A, Haji K, et al.

(2) CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected PatientsCellsOctober 22, 2022D'Alterio C, Giardino A, Scognamiglio G, Butturini G, Portella L, Guardascione G, Frigerio I, Montella M, Gobbo S, Martignoni G, et al.

(3) Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer PatientsCancersApril 6, 2022D'Alterio C, Spina A, Arenare L, Chiodini P, Napolitano M, Galdiero F, Portella L, Simeon V, Signoriello S, Raspagliesi F, et al.

(4) Combination of IDO1^high and CCL19^low expression in the tumor tissue reduces survival in HPV positive cervical cancerJournal of reproductive immunologyFebruary 1, 2022Jayakumar H, Seetharaman A, Sunder Singh S, Dhandapani H, Subramani J, Ganeshrajah S, Thangarajan R, Ramanathan P.

(5) Role of CCR3 in respiratory syncytial virus infection of airway epithelial cellsiScienceDecember 17, 2021Wellemans V, Benhassou HA, Fuselier E, Bellesort F, Dury S, Lebargy F, Dormoy V, Fichel C, Naour RL, Gounni AS, et al.

(6) Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesisPLoS pathogensApril 1, 2021Armani-Tourret M, Zhou Z, Gasser R, Staropoli I, Cantaloube-Ferrieu V, Benureau Y, Garcia-Perez J, Pérez-Olmeda M, Lorin V, Puissant-Lubrano B, et al.

(7) Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer's diseaseNature communicationsOctober 23, 2020McQuade A, Kang YJ, Hasselmann J, Jairaman A, Sotelo A, Coburn M, Shabestari SK, Chadarevian JP, Fote G, Tu CH, et al.

(8) Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal AdenocarcinomaBiomedicinesOctober 22, 2020Liu D, Steins A, Klaassen R, van der Zalm AP, Bennink RJ, van Tienhoven G, Besselink MG, Bijlsma MF, van Laarhoven HWM.

(9) Clinicopathologic determinants of pathologic treatment response in neoadjuvant treated rectal adenocarcinomaAnnals of diagnostic pathologyApril 1, 2020González I, Bauer PS, Chapman WC Jr, Alipour Z, Rais R, Liu J, Chatterjee D.

(11) High CXCR4 Expression Predicts a Poor Prognosis in Resected Lung Adenosquamous CarcinomaJournal of CancerJanuary 1, 2020Zhu Q, Luo R, Gu J, Hou Y, Chen Z, Xu F, Wang L, Mao W, Lu C, Ge D.

(12) Chemokine Receptor Expression Pattern Correlates to Progression of Conjunctival Melanocytic LesionsInvestigative ophthalmology & visual scienceJuly 1, 2019van Ipenburg JA, de Waard NE, Naus NC, Jager MJ, Paridaens D, Verdijk RM.

(13) Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapyPloS oneJanuary 1, 2019Giampieri R, Piva F, Occhipinti G, Bittoni A, Righetti A, Pagliaretta S, Murrone A, Bianchi F, Amantini C, Giulietti M, et al.

(14) Breast Cancer: An Examination of the Potential of ACKR3 to Modify the Response of CXCR4 to CXCL12International journal of molecular sciencesNovember 14, 2018Del Molino Del Barrio I, Wilkins GC, Meeson A, Ali S, Kirby JA.

(15) Tumor microenvironment in functional adrenocortical adenomas: immune cell infiltration in cortisol-producing adrenocortical adenomaHuman pathologyJuly 1, 2018Kitawaki Y, Nakamura Y, Kubota-Nakayama F, Yamazaki Y, Miki Y, Hata S, Ise K, Kikuchi K, Morimoto R, Satoh F, et al.

(20) Cell-based therapy using miR-302-367 expressing cells represses glioblastoma growthCell death & diseaseMarch 30, 2017Fareh M, Almairac F, Turchi L, Burel-Vandenbos F, Paquis P, Fontaine D, Lacas-Gervais S, Junier MP, Chneiweiss H, Virolle T.

CXCR4 Antibody